Ventyx Biosciences Announces Departure of Chief Financial Officer
Ventyx Biosciences, Inc. (Nasdaq: VTYX), a forward-thinking clinical-stage biopharmaceutical company, is in the spotlight due to a notable change in its leadership. Renowned for its dedication to creating innovative oral therapies for inflammatory diseases, Ventyx has announced that Martin Auster, M.D., has resigned from his role as Chief Financial Officer, effective immediately.
Leadership Transition
During this transitional period, Roy Gonzales, CPA, MBA, who has been the Senior Vice President of Finance, will step in as the interim Principal Financial Officer and interim Principal Accounting Officer to meet SEC requirements. As Ventyx moves forward, the company has begun an active search for a new CFO who aligns with its mission to enhance healthcare solutions.
Reflections from Leadership
Raju Mohan, Ph.D., the CEO of Ventyx, shared his appreciation for Dr. Auster's contributions, stating, “Marty has been a valued member of our executive team over these past three years. His leadership has been instrumental during critical phases, including our successful initial public offering and ongoing financial governance. We wish him well in his future endeavors.”
What Lies Ahead
Looking back on his time with the company, Dr. Auster remarked, “It has been a privilege to work as part of Ventyx’s leadership team and I am proud of our accomplishments. I wish the Company great success in the future.” This transition marks the beginning of a new chapter for Ventyx, which is well-positioned to continue its growth in developing vital therapies.
About Ventyx Biosciences
Ventyx Biosciences is on a mission to transform the treatment landscape for individuals affected by inflammatory diseases. The company is dedicated to developing innovative oral therapies aimed at replacing conventional injectable treatments. With a robust pipeline that includes clinical programs targeting key therapeutic areas such as NLRP3, S1P1R, and TYK2, Ventyx is strategically poised to lead in the oral therapy sector for both peripheral and neuroinflammatory conditions.
Ventyx's commitment to addressing unmet medical needs places it at the forefront of biopharmaceutical innovation. Their goal is to change the current treatment delivery paradigm by offering patients more accessible and effective oral options.
Investor Relations Contact
For more information, please reach out to:
Patti Bank
Managing Director
ICR Westwicke
(415) 513-1284
IR@ventyxbio.com
Frequently Asked Questions
What prompted the departure of Martin Auster from Ventyx?
Martin Auster's departure as Chief Financial Officer is part of a leadership transition as the company looks to appoint a new CFO to support its growth strategies.
Who will serve as the interim CFO at Ventyx?
Roy Gonzales, the current Senior Vice President of Finance, will take on the roles of interim Principal Financial Officer and interim Principal Accounting Officer during this transition.
What initiatives will Ventyx focus on moving forward?
Ventyx will continue to concentrate on developing innovative oral therapies for inflammatory diseases, aiming to provide effective treatment options that can replace traditional injectable therapies.
How has Ventyx recognized Dr. Auster's contributions?
The CEO of the company has expressed gratitude for Dr. Auster’s leadership during critical phases, including the successful execution of the initial public offering and various financial management initiatives.
Where can I find more information about Ventyx Biosciences?
For additional details on Ventyx and its groundbreaking therapies, please visit the company’s official website at www.ventyxbio.com.
